A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 29 May 2018 Status changed from recruiting to active, no longer recruiting.
- 01 May 2018 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.
- 01 May 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2019.